AU2013299559B2 - Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof - Google Patents

Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof Download PDF

Info

Publication number
AU2013299559B2
AU2013299559B2 AU2013299559A AU2013299559A AU2013299559B2 AU 2013299559 B2 AU2013299559 B2 AU 2013299559B2 AU 2013299559 A AU2013299559 A AU 2013299559A AU 2013299559 A AU2013299559 A AU 2013299559A AU 2013299559 B2 AU2013299559 B2 AU 2013299559B2
Authority
AU
Australia
Prior art keywords
formula
compound
occurs
enantiomerically pure
enantiomerically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013299559A
Other languages
English (en)
Other versions
AU2013299559A1 (en
Inventor
Benjamin M. Cohen
Gregg B. Feigelson
William W. Leong
John F. Traverse
Chengmin Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of AU2013299559A1 publication Critical patent/AU2013299559A1/en
Application granted granted Critical
Publication of AU2013299559B2 publication Critical patent/AU2013299559B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2013299559A 2012-08-09 2013-08-08 Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof Active AU2013299559B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09
US61/681,477 2012-08-09
PCT/US2013/054099 WO2014025978A1 (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Publications (2)

Publication Number Publication Date
AU2013299559A1 AU2013299559A1 (en) 2015-02-05
AU2013299559B2 true AU2013299559B2 (en) 2017-08-17

Family

ID=49035933

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013299559A Active AU2013299559B2 (en) 2012-08-09 2013-08-08 Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Country Status (19)

Country Link
US (2) US9309220B2 (enExample)
EP (2) EP3466942B1 (enExample)
JP (1) JP6444866B2 (enExample)
KR (1) KR20150041650A (enExample)
CN (1) CN104718202B (enExample)
AU (1) AU2013299559B2 (enExample)
BR (1) BR112015002183A2 (enExample)
CA (2) CA2879151C (enExample)
CR (1) CR20150051A (enExample)
EC (1) ECSP15004585A (enExample)
ES (2) ES2712652T3 (enExample)
HK (1) HK1211577A1 (enExample)
IL (1) IL236925A0 (enExample)
IN (1) IN2015DN00845A (enExample)
MX (2) MX2015001633A (enExample)
PH (1) PH12015500214A1 (enExample)
RU (1) RU2015108057A (enExample)
SG (1) SG11201500984QA (enExample)
WO (1) WO2014025978A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201501062SA (en) 2010-02-11 2015-04-29 Celgene Corp Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
CA2935495C (en) 2013-01-14 2021-04-20 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
EP2968334A4 (en) 2013-03-14 2016-08-03 Deuterx Llc 3- (SUBSTITIERTES-4-OXO-quinazolin-3 (4H) -yl) -3-deutero-PIPERIDINE-2,6-DIONE DERIVATIVES
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
JP7399846B2 (ja) 2017-08-21 2023-12-18 セルジーン コーポレイション （ｓ）－ｔｅｒｔ－ブチル４，５－ジアミノ－５－オキソペンタノエートの調製プロセス
AU2019351811B2 (en) 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (zh) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 制备3-亚苄基-2-（7’-喹啉）-2,3-二氢-异吲哚-1-酮类化合物的方法
CA3159978A1 (en) * 2019-12-02 2021-06-10 Celgene Corporation Therapy for the treatment of cancer
CN113896711A (zh) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 杂环类免疫调节剂
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
CN121002005A (zh) * 2023-04-11 2025-11-21 上海科胜药物研发有限公司 一种芳基甲氧基异吲哚啉衍生物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005972A1 (en) * 2005-06-30 2007-01-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
WO2011100380A1 (en) * 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
EP2479172B1 (en) 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
EP2142534B1 (en) 2007-03-20 2016-08-10 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
WO2011111053A1 (en) 2010-03-08 2011-09-15 Natco Pharma Limited Anhydrous lenalidomide form-i
ES2671608T3 (es) 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007005972A1 (en) * 2005-06-30 2007-01-11 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
WO2011100380A1 (en) * 2010-02-11 2011-08-18 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same

Also Published As

Publication number Publication date
CN104718202B (zh) 2018-11-20
EP3466942A1 (en) 2019-04-10
IN2015DN00845A (enExample) 2015-06-12
HK1211577A1 (en) 2016-05-27
WO2014025978A1 (en) 2014-02-13
BR112015002183A2 (pt) 2017-07-04
ES2914876T3 (es) 2022-06-17
PH12015500214A1 (en) 2015-04-27
RU2015108057A (ru) 2016-09-27
AU2013299559A1 (en) 2015-02-05
ECSP15004585A (es) 2015-12-31
JP6444866B2 (ja) 2018-12-26
MX385058B (es) 2025-03-14
ES2712652T3 (es) 2019-05-14
CA3108974A1 (en) 2014-02-13
US20160251333A1 (en) 2016-09-01
IL236925A0 (en) 2015-03-31
CA2879151A1 (en) 2014-02-13
US20140046058A1 (en) 2014-02-13
US9975872B2 (en) 2018-05-22
CN104718202A (zh) 2015-06-17
CR20150051A (es) 2015-05-11
EP2882736B1 (en) 2019-01-09
CA2879151C (en) 2021-03-30
CA3108974C (en) 2023-04-04
SG11201500984QA (en) 2015-04-29
MX2015001633A (es) 2015-04-08
KR20150041650A (ko) 2015-04-16
JP2015524481A (ja) 2015-08-24
US9309220B2 (en) 2016-04-12
EP2882736A1 (en) 2015-06-17
EP3466942B1 (en) 2022-04-20

Similar Documents

Publication Publication Date Title
AU2013299559B2 (en) Processes for the preparation of (S)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof
CN114174281A (zh) 细胞周期蛋白依赖性激酶7(cdk7)的降解剂及其用途
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
WO2015057626A1 (en) QUINOLINYL MODULATORS OF RORyT
JP5892550B2 (ja) 縮合イミダゾール誘導体
JP7399846B2 (ja) （ｓ）－ｔｅｒｔ－ブチル４，５－ジアミノ－５－オキソペンタノエートの調製プロセス
AU2006331676A1 (en) Nitroimidazole compounds
JP2025534444A (ja) ホスホルアミダート化合物及びその用途
CA2856824A1 (en) Cyclic urea derivatives as androgen receptor antagonists
JP2022505827A (ja) 置換インドール二量体の化合物
CN111936488A (zh) 用于治疗寄生虫感染的新颖化合物
JP2024506387A (ja) 腎線維症を治療するためのオキサジアゾリルジヒドロピラノ［２，３‐ｂ］ピリジン系ＨＩＰＫ２阻害剤
WO2016151011A1 (en) 2-homopiperazine-1-yl-4h-1,3-benzothiazine-4-one derivatives and process for the preparation of 2- (homo)piperazine 1,3-benzothiazine-4-one hydrochlorides
WO2025260063A2 (en) Methods of preparing a prmt5 inhibitor
AU3126200A (en) Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
HK1215436A1 (zh) 取代的(r)-3-(4-甲基氨基甲酰基-3-氟苯基氨基)四氫呋喃-3-甲酸(變體)和其酯，其製備方法和用途
IL262151A (en) Processes for making oxytazine-like compounds
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)